NASDAQ:MTVA MetaVia (MTVA) Stock Price, News & Analysis $1.11 -0.08 (-6.72%) Closing price 05/15/2026 04:00 PM EasternExtended Trading$1.14 +0.03 (+3.15%) As of 05/15/2026 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About MetaVia Stock (NASDAQ:MTVA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get MetaVia alerts:Sign Up Key Stats Today's Range$1.11▼$1.2050-Day Range$0.97▼$1.6352-Week Range$0.97▼$19.03Volume36,140 shsAverage Volume150,139 shsMarket Capitalization$5.73 millionP/E RatioN/ADividend YieldN/APrice Target$26.50Consensus RatingHold Company Overview MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc., formerly known as NeuroBo Pharmaceuticals Inc., is based in CAMBRIDGE, Mass. Read More MetaVia Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks48th Percentile Overall ScoreMTVA MarketRank™: MetaVia scored higher than 48% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingHold Consensus RatingMetaVia has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialMetaVia has a consensus price target of $26.50, representing about 2,287.4% upside from its current price of $1.11.Amount of Analyst CoverageMetaVia has only been the subject of 2 research reports in the past 90 days.Read more about MetaVia's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for MetaVia are expected to decrease in the coming year, from ($2.72) to ($3.01) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MetaVia is -0.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MetaVia is -0.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMetaVia has a P/B Ratio of 0.48. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.58% of the float of MetaVia has been sold short.Short Interest Ratio / Days to CoverMetaVia has a short interest ratio ("days to cover") of 0.59, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in MetaVia has recently increased by 25.78%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMetaVia does not currently pay a dividend.Dividend GrowthMetaVia does not have a long track record of dividend growth. News and Social Media2.5 / 5News Sentiment0.04 News SentimentMetaVia has a news sentiment score of 0.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for MetaVia this week, compared to 2 articles on an average week.MarketBeat Follows6 people have added MetaVia to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, MetaVia insiders have not sold or bought any company stock.Percentage Held by Insiders0.80% of the stock of MetaVia is held by insiders.Percentage Held by Institutions1.37% of the stock of MetaVia is held by institutions.Read more about MetaVia's insider trading history. Receive MTVA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MetaVia and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MTVA Stock News HeadlinesMetaVia (MTVA) Stock Forecast & Price TargetMay 14 at 10:33 PM | investing.comMetaVia Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 14 at 4:05 PM | prnewswire.com$30 stock to buy before Starlink goes public (WATCH NOW!)A little-known stock pick with money-doubling potential over the next year is revealed for free in the first three minutes of a new video. This company is a critical piece of Elon Musk's fast-growing Starlink technology. It could climb 100 percent or more over the next year as Elon brings Starlink public in what may be the biggest IPO in history. No credit card is required to get the ticker.May 17 at 1:00 AM | Paradigm Press (Ad)MetaVia to Present New DA-1726 Obesity Data at EASLMay 11, 2026 | tipranks.comMetaVia to Present Data Highlighting DA-1726, a GLP-1/Glucagon Dual Agonist, in a Late-Breaking Poster Presentation at the EASL Congress 2026May 11, 2026 | prnewswire.comMetaVia (MTVA) Expected to Announce Earnings on WednesdayMay 11, 2026 | americanbankingnews.comMetaVia (MTVA) price target decreased by 71.04% to 19.72April 29, 2026 | msn.comMetaVia Stock Dividends | NASDAQ:MTVA | BenzingaApril 28, 2026 | benzinga.comSee More Headlines MTVA Stock Analysis - Frequently Asked Questions How have MTVA shares performed this year? MetaVia's stock was trading at $8.42 on January 1st, 2026. Since then, MTVA stock has decreased by 86.8% and is now trading at $1.11. How were MetaVia's earnings last quarter? MetaVia Inc. (NASDAQ:MTVA) released its quarterly earnings results on Thursday, May, 14th. The company reported ($0.79) EPS for the quarter, missing the consensus estimate of ($0.76) by $0.03. When did MetaVia's stock split? MetaVia's stock reverse split on Friday, December 5th 2025.The 1-11 reverse split was announced on Tuesday, December 2nd 2025. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, December 4th 2025. An investor that had 100 shares of stock prior to the reverse split would have 9 shares after the split. When did MetaVia IPO? MetaVia (MTVA) raised $36 million in an IPO on Thursday, June 23rd 2016. The company issued 3,000,000 shares at $11.00-$13.00 per share. How do I buy shares of MetaVia? Shares of MTVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings5/14/2026Today5/17/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (4m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 MTVA's financial health is in the Red zone, according to TradeSmith. MTVA has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MTVA Previous SymbolNASDAQ:NRBO CIK1638287 Webwww.neurobopharma.com Phone857-702-9600Fax734-293-0444Employees8Year FoundedN/APrice Target and Rating Average Price Target for MetaVia$26.50 High Price Target$33.00 Low Price Target$20.00 Potential Upside/Downside+2,287.4%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($8.36) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$12.97 million Net MarginsN/A Pretax MarginN/A Return on Equity-184.96% Return on Assets-88.79% Debt Debt-to-Equity RatioN/A Current Ratio1.93 Quick Ratio1.93 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.31 per share Price / Book0.48Miscellaneous Outstanding Shares5,160,000Free Float5,123,000Market Cap$5.73 million OptionableN/A Beta0.59 Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:MTVA) was last updated on 5/17/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredSpaceX Goes Public. Here's What Happens To Your IRA.When SpaceX goes public, fund managers will sell existing portfolio holdings to fund the move. Trillions in as...Americas Gold Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MetaVia Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MetaVia With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
